Phathom Pharma Upgraded by Barclays to Overweight $18 Target
Barclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Explore options for retirement accounts at 50. Make informed choices to secure your financial future.
24,046 articlesBarclays lifts Phathom Pharmaceuticals to Overweight with an $18 target, citing a stronger 2026 revenue trajectory an...
Gas prices surged this week, lifting the national average price by about 33 cents. The rise comes as refinery mainten...
Tech giants drive a broad market surge as AI earnings power gains push the Nasdaq toward a nasdaq defy gravity record...
A veteran Wall Street observer reveals a clean, repeatable way to find the next big chip stock winners. Read how to s...
Investors are watching whether Alphabet can become the most valuable company by turning Google Cloud into a high-marg...
Keystone reveals a sizable new stake in the IDEF defense ETF, signaling growing investor interest in defense and indu...
When Road releases its Q2 results, the transcript hides clues about growth and risk. This guide translates the road 2...
Eli Lilly's ascent to the top of the drug charts centers on a single family of medicines. This article breaks down wh...
In volatile markets, some investors look to physical metals for ballast. This article breaks down why ishares silver ...
HSBC downgraded Trade Desk to Reduce with a $20 target, joining a wave of caution as ad-tech faces a shift toward ret...
Abcellera's Q1 2026 earnings transcript provides key clues about the path to 2026. This guide breaks down revenue dri...
As AI tools land in personal finance, results remain uneven for banks, fintechs, and everyday users. This report trac...